openPR Logo
Press release

Dendritic Cell Cancer Vaccine Market Projected to Reach USD 2.29 Billion by 2034, Growing at a CAGR of 12.0%

05-06-2025 10:43 AM CET | Health & Medicine

Press release from: Polaris Market Research & Consulting

Dendritic Cell Cancer Vaccine Market

Dendritic Cell Cancer Vaccine Market

The Global Dendritic Cell Cancer Vaccine Market Was Valued At USD 737.46 Million In 2024. It Is Projected To Reach USD 2,285.32 Million By 2034, Exhibiting A Compound Annual Growth Rate (CAGR) Of 12.0% From 2025 To 2034.

Market Overview
Dendritic cell (DC) vaccines combine vaccine and cell therapy approaches. Dendritic cells act like immune system factories, producing molecules that activate crucial components of both the innate and adaptive immune systems. Due to their specialized role in antigen presentation, DCs are key orchestrators in initiating antitumor immune responses.
Dendritic cells can be used as vaccines by loading them with peptides or small fragments of tumor antigens, which are then administered into the body. Through site-specific delivery, researchers have found that injecting the DC vaccine directly into tumors can trigger a broader cascade of immune responses, activating multiple immune components to fight the cancer.

Get Exclusive Sample Pages of This Report:
https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market/request-for-sample

Competitive Landscape Analysis
Prominent contenders in the market are adopting strategic initiatives for the advancement of innovative therapies. Some of the companies which are currently dominating the market are:
• Activartis Biotech GmbH
• Batavia Bioservices B.V.
• DanDrit Biotech
• DCPrime
• Elios Therapeutics
• GlaxoSmithKline plc
• ImmunoCellular Therapeutics
• Mendus
• Northwest Biotherapeutics
• Sanpower Corporation

Dendritic Cell Cancer Vaccine Market Report Highlights
• The dendritic cell cancer vaccine market, by product, is segmented into CreaVax, sipuleucel-T, and others. The sipuleucel-T segment dominated the dendritic cell cancer vaccine market share in 2024 due to its ability to enhances the immune response to prostatic acid phosphatase antigen.

• The market, by end use, is segmented into pediatrics and adults. The adult segment dominated the market share in 2024. This dominance is attributed to the higher incidence of cancer among adults, leading to increased demand for effective immunotherapeutic interventions.

• North America accounted for a major dendritic cell cancer vaccine market revenue share in 2024 due to well-established healthcare infrastructure, significant investments in cancer immunotherapy, and a high prevalence of cancer cases.

Request for a Discount on this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market/request-for-discount-pricing

Market Drivers
Progressions in Personalized Immunotherapy: The market demand is pushed by notable advancements in personalized immunotherapy. Dendritic cells, as antigen-presenting cells, play an important part in commencing and controlling immune reactions against tumors. The advancement of vaccines using autologous dendritic cells packed with tumor-particular antigens has displayed assurance in evoking earmarked immune responses, placing the dendritic cell cancer vaccine market on a growth trajectory.

Growing Research and Clinical Trials: A surge in research ventures and clinical trials concentrating on dendritic cell-based vaccines are emerging markets in cancer therapy. As of 2024, the clinicaltrials.gov website enumerates over 1900 trials linked with the terminology cancer vaccines, with 186 being phase 3 trials. This string pipeline mirrors the scientific community's pledge to traverse the productivity of dendritic cell vaccines covering several cancer types.
Segmentation Outlook
By Product Outlook (Revenue - USD Million, 2020-2034)
• CreaVax
• Sipuleucel-T
• Others

By End Use Outlook (Revenue - USD Million, 2020-2034)
• Paediatrics
• Adults

Explore The Complete Comprehensive Report Here:
https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market

Geographical Landscape
Regionally, the market is segmented into North America, Europe, Asia Pacific, South America and the Middle East and Africa.

North America accounted for the largest dendritic cell cancer vaccine market share in 2024 owing to entrenched healthcare framework, notable funding in cancer immunotherapy and elevated existence of cancer cases.

Asia Pacific is experiencing rapid growth due to the growing healthcare funding and a global cancer vaccine demand.

• North America (US, Canada)
• Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Argentina, and Rest of Latin America)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa, and Rest of Middle East & Africa)

More Trending Latest Reports by Polaris Market Research:
Operational Technology (OT) Security Market
https://www.polarismarketresearch.com/industry-analysis/operational-technology-ot-security-market

Forage Market
https://www.polarismarketresearch.com/industry-analysis/forage-market

Farm Management Software Market
https://www.polarismarketresearch.com/industry-analysis/farm-management-software-market

Medical Devices Market
https://www.polarismarketresearch.com/industry-analysis/medical-devices-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dendritic Cell Cancer Vaccine Market Projected to Reach USD 2.29 Billion by 2034, Growing at a CAGR of 12.0% here

News-ID: 4000946 • Views:

More Releases from Polaris Market Research & Consulting

Europe Armor Materials Market to Reach USD 6.09 Billion by 2034, Growing at 7.0% CAGR
Europe Armor Materials Market to Reach USD 6.09 Billion by 2034, Growing at 7.0% …
Market Size and Share: Europe Armor Materials Market is currently valued at USD 3.10 billion in 2024 and is anticipated to generate an estimated revenue of USD 6.09 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 7% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034 Polaris Market Research has introduced the latest market research
Europe Antibody Specificity Testing Market Projected to Hit USD 433.81 Million by 2034, Growing at a CAGR of 7.3%
Europe Antibody Specificity Testing Market Projected to Hit USD 433.81 Million b …
The quantitative market research report published by Polaris Market Research on Europe Antibody Specificity Testing Market aims to educate users with an in-depth understanding of a rapidly growing market. The study details important facts and figures, expert opinions, and major developments across the globe. The research study serves as a vital source of information with the historical data, Europe Antibody Specificity Testing Market size, financial data, and projected future growth.
U.S. Extended Detection and Response (XDR) Market to Reach USD 24.86 Billion by 2034, Advancing at a CAGR of 30.6%
U.S. Extended Detection and Response (XDR) Market to Reach USD 24.86 Billion by …
The quantitative market research report published by Polaris Market Research on U.S. Extended Detection and Response (XDR) Market aims to educate users with an in-depth understanding of a rapidly growing market. The study details important facts and figures, expert opinions, and major developments across the globe. The research study serves as a vital source of information with the historical data, U.S. Extended Detection and Response (XDR) Market size, financial data,
Europe Ethylene Propylene Diene Monomer (EPDM) Market Set to Reach USD 1.52 Billion by 2034, Expanding at 4.1% CAGR
Europe Ethylene Propylene Diene Monomer (EPDM) Market Set to Reach USD 1.52 Bill …
The quantitative market research report published by Polaris Market Research on Europe Ethylene Propylene Diene Monomer (EPDM) Market aims to educate users with an in-depth understanding of a rapidly growing market. The study details important facts and figures, expert opinions, and major developments across the globe. The research study serves as a vital source of information with the historical data, Europe Ethylene Propylene Diene Monomer (EPDM) Market size, financial data,

All 5 Releases


More Releases for Dendritic

Dendritic Cell Therapies Market Drivers, Challenges, and Future Prospects
The Dendritic Cell (DC) Therapies Market focuses on the development of treatments that leverage dendritic cells-the most potent antigen-presenting cells in the human immune system-to activate targeted and robust immune responses against cancer, infectious diseases, and chronic disorders. As a central component of modern immunotherapy, dendritic cell therapies offer a personalized and precise approach by presenting tumor-specific or disease-specific antigens to T-cells, initiating powerful immune activation. Download Full PDF Sample Copy
03-23-2025 | Health & Medicine
IMMU
The key to fighting cancer: Dendritic cell therapy ?
In today's world, where we are constantly faced with new challenges in the field of cancer treatment, it is crucial to pursue innovative approaches. One promising method is therapy with tumor antigen-loaded dendritic cells. A functioning immune system plays a central role in fighting tumors and metastases. But how can we specifically support the immune system? Autologous dendritic cell therapy, produced from the blood of the affected patient, offers a promising
Primary Catalyst Driving Dendritic Cell Cancer Vaccine Market Evolution in 2025: …
"What market dynamics are playing a key role in accelerating the growth of the dendritic cell cancer vaccine market? The rising number of cancer cases is expected to drive the growth of the dendritic cell cancer vaccine market. Cancer is marked by the uncontrolled growth of abnormal cells, which disrupt normal bodily functions. Various factors, including lifestyle choices and genetic predispositions, impact cancer rates. Dendritic cell cancer vaccines help stimulate the
Revolutionizing Cancer Treatment: The Future of Dendritic Cell Vaccines
"The Business Research Company recently released a comprehensive report on the Global Dendritic Cell Cancer Vaccine Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, the dendritic
Dendritic Cell Cancer Vaccine Market Dendritic Cell Cancer Vaccine Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Advent of Dendritic Vaccine in Oncology 2. Cataloging towards Dendritic Cells 3. Dendritic Cells Mechanizing Immune Response 3.1 Antigen Appearance Leads to Cellular Immune Responses 3.2 Stacking of Distinct Antigens over Dendritic Cells 3.3 Dendritic Cells Source and Subsets 3.4 Trail towards Maturation 3.5 Stimulation Initiates Maturation 3.6 Migration to Lymph Node 3.7
Global Dendritic Cell Cancer Vaccine Market & Dendritic Cell Cancer Vaccine Clin …
Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community